Latest publications publications
Malignant Hypertension:
A Systemic Cardiovascular Disease: JACC Review Topic of the Week
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial
We are very pleased to present the article "A machine learning-based lung ultrasound algorithm for the diagnosis of acute heart failure."
Ensemble
for research
A network of excellence
The INI-CRCT network is a French research network of excellence labelled by the F-CRIN national infrastructure of scientific and clinical research networks.
Improve patient prognosis
Composed of men and women whose mission, in the service of scientific excellence and leadership in the cardio-renal field, is to improve the cardiovascular prognosis of patients with kidney failure.
Our network
Active members. Research projects. Publications
Here you'll find access to all our themes.
Our VALUES & STRENGTHS
Excellence
Leadership
Respect
Parity
Expertise
Approach quality
Projects
Paladin Network
News from the network and partners
Here you can find our latest publications - articles - congresses
CERTIFICATION
We are delighted to inform you that the network has successfully maintained ISO 9001 certification. This achievement demonstrates our commitment to operational excellence, satisfaction and continuous improvement. We would like to thank our team for their involvement and dedication in making this certification possible.
iSCCa
The first iSCCa international symposium will be held on October 10 and 11, 2024 in Nice. INI-CRCT member Prof. Georges Lefthoriotis and the International Network On Ectopic Calcification (INTEC) will be delighted to welcome you.
EMPEROR
Drug treatment with empagliflozin was beneficial in people with heart failure with preserved ejection fraction: plain language summary of the EMPEROR-Preserved study
EMPEROR
Drug treatment with empagliflozin lowered risk for hospitalization in people with heart failure with reduced ejection fraction: plain language summary of the EMPEROR-Reduced study
ALCHEMIST: Presented at the ASN 2023 congress in early NovemberProf. Rossignol comments on the results of the ALCHEMIST trial, which included chronic haemodyalized patients at major cardiovascular risk for the first time in a cardiovascular outcomes trial.
Our interactive brochure
